Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$24.50
Change (%) Stock is Up 0.75 (3.16%)
Volume169,128
Data as of 06/26/17 12:52 p.m. ET

Latest News

06/14/17
Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference
06/03/17
New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections
05/24/17
Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017
05/08/17
Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.